Pricing for Oncology Biosimilars—Reply
In Reply I thank Drs Jensen and Tichy for the opportunity to respond to the comments on our article on hospital adoption and pricing for oncology biosimilars. Their comments are factually correct and add insight into the complex process of drug payment and strengthen the core message of our article.
Original Source
Read the full article at Jamanetwork →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.